Inositol

Inositol

1. Identity: Chemical Names, Natural Sources, and Common Forms

Inositol — systematically named cyclohexane-1,2,3,4,5,6-hexol — has the molecular formula C₆H₁₂O₆ and is a sixfold alcohol (polyol) of cyclohexane. Nine possible stereoisomers of inositol exist, including cis-, epi-, allo-, myo-, muco-, neo-, (+)-chiro, (−)-chiro-, and scyllo-inositols. The most prominent form, widely occurring in nature, is cis-1,2,3,5-trans-4,6-cyclohexanehexol, commonly known as myo-inositol (formerly called meso-inositol).

Biosynthetically, inositols derive from sugars and possess a molecular structure very similar to simple sugars, placing them at the boundary between primary and secondary metabolites. As primary metabolites they are essential cellular components in the form of phospholipid derivatives; as secondary metabolites they are involved in a plethora of signaling pathways. myo-Inositol derives directly from D-glucose, and all known inositols, including stereoisomers and derivatives, are the results of metabolic processes on this unique molecule.

Despite eight out of the nine inositol isomers occurring naturally, only myo-inositol, scyllo-inositol, and D-chiro-inositol have been detected as major inositols present in mammalian tissue. Besides myo-inositol, the other naturally occurring (albeit uncommon) stereoisomers are scyllo-, muco-, D-chiro-, and neo-inositol.

Inositol is biosynthesized by cells in many different tissues, including the brain, testis, liver, and especially the kidneys. It is commonly found in tissues within the skeletal system, reproductive system, heart, and nerve systems, including large amounts in spinal cord nerves, cerebrospinal fluid, and the brain.

Dietary Sources

The human diet provides inositols — mostly myo-inositol — both from animal sources in a free form or as inositol-containing phospholipids, and from plant foodstuffs as the phosphate derivative known as inositol hexaphosphate (IP6) or phytic acid. Phytic acid, the main storage form of phosphorus and a primary source of inositol, is found in the bran of grains and seeds. Other inositol-containing foods include almonds, walnuts, Brazil nuts, oats, beans and peas, cantaloupe, and citrus fruits (except lemons); for example, 4 oz of grapefruit juice contains around 470 mg of myo-inositol.

The typical American diet provides an estimated 500 to 1,000 milligrams (mg) daily. Western diets can provide around 0.5–1 g/day of myo-inositol. Dietary caffeine intake (particularly from coffee) increases the need for myo-inositol. Increasing age, antibiotic use, sugar and refined carbohydrate intake, sodium deficiency, insulin resistance, and type 1 and type 2 diabetes all increase the need for myo-inositol.

D-Chiro-Inositol and Pinitol

D-chiro-inositol is mainly obtained as the methylated form D-pinitol (3-O-methyl-D-chiro-inositol), which is demethylated to DCI under acidic conditions in the gastrointestinal tract. D-pinitol acts as an osmolyte in plants, allowing tolerance to heat, high salinity, and drought stress. The Leguminosae family is a major source of D-pinitol, especially carob pods, which provide 10–80 g/kg of the compound.

Common Supplemental Forms and Preparations

Dietary supplements may contain many forms of inositol, including inositol hexaphosphate (IP6 or phytate), myo-inositol, and D-chiro-inositol. Inositol is available in pill and powder forms for oral administration. Many PCOS-focused supplements combine myo-inositol with D-chiro-inositol in a 40:1 ratio, which mirrors the natural balance of these two forms in the body. Inositol is used as a nutritive supplement in infant formula and is available as an over-the-counter supplement.

2. Traditional and Historical Use

Although myo-inositol had been discovered in extracts of animal tissues almost 100 years earlier, interest in its potential nutritional role first occurred in 1940 when it was reported to be a new vitamin required for normal growth, hair, and skin of the mouse — designated the "mouse antialopecia factor." Several groups subsequently found dietary supplements of myo-inositol to stimulate the growth of several species (chicks, turkeys, rats, mice) in ways dependent on shortages of other factors including pantothenic acid, biotin, and folate.

Inositol is traditionally regarded as one of the B vitamins. However, it is not truly a B vitamin but rather works in association with B vitamins, including pyridoxine (B6), folic acid (B9), pantothenic acid (B5), and PABA. Inositol may also be referred to as "vitamin B8," as it was initially thought to be a vitamin due to its nutritional benefits; however, it is now known to be a sugar with a chemical structure similar to glucose. Dietary uptake and endogenous biosynthesis are sufficient to meet the body's inositol requirements, and an inositol deficiency syndrome has not been identified.

Historically, myo-inositol was initially studied for its role in insulin sensitivity and diabetic neuropathy, given its presence in dietary sources and its importance in cellular signaling pathways. The initial rationale for attempts to treat depression by dietary supplementation with inositol came from the finding that inositol was shown to be decreased in the cerebrospinal fluid (CSF) of depressed patients (Barkai, 1978), although others did not replicate this finding.

3. Key Constituents and Mechanisms of Action

The Phosphatidylinositol (PI) Second Messenger System

Inositol may be involved in neurotransmitter synthesis and is a precursor to the phosphatidylinositol (PI) cycle, an important intracellular second messenger system. By changing the PI cycle, inositol may exert intracellular changes that are similar to those seen when a post-synaptic receptor is activated, but without the need to activate that receptor, effectively mimicking receptor activation at the cellular level.

When a cell receives an external signal through a receptor, phosphatidylinositol bisphosphate (PIP2) is hydrolyzed by the enzyme phospholipase C (PLC) to generate two secondary messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium ions from intracellular stores, which are essential for various cellular activities such as muscle contraction, secretion, and metabolism. DAG activates protein kinase C (PKC), which phosphorylates target proteins to modulate their function.

The PI cycle is the second messenger system for numerous neurotransmitter receptors, including cholinergic muscarinic, alpha-1 noradrenergic, serotonin (5-HT₂A and 5-HT₂C), and dopaminergic D₁ receptors. The activity of lithium and antiepileptic mood-stabilizing medications in affecting inositol uptake provides an additional rationale for the use of inositol in psychiatric treatment and suggests that stable inositol signaling may be crucial in mood stability, with elevated inositol implicated in mania and depleted inositol implicated in depression.

Serotonergic and Neurological Mechanisms

A possible antidepressant mechanism of inositol involves the signal transduction of serotonin, one of the key neurotransmitters associated with the pathogenesis of mood disorders. However, inositol does not seem to have a direct effect on synapses by inhibiting the reuptake of monoamines; neither acute nor chronic administration of inositol has demonstrated an effect on brain levels of monoamines. It has been suggested that the therapeutic activity of inositol may be related to the modulation of serotonin and/or norepinephrine receptors and to an effect on the signal transduction pathway.

Insulin Signaling and Metabolic Mechanisms

The most important members of the phosphoinositide family include phosphatidylinositol (4,5)-bisphosphate (PIP2), a substrate for phosphoinositide 3-kinase (PI3K), whose phosphorylation and conversion into phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is a key step in the insulin/IGF-1 pathway. Phosphoglycans are involved in the glycosyl-phosphatidylinositol/inositol phosphoglycans pathway as second messengers, regulating different cellular pathways including insulin sensitization and cellular proliferation regulation.

Given the shared transporter systems between glucose and myo-inositol, hyperglycemia can competitively inhibit cellular inositol uptake, potentially increasing inositol requirements. Aging, insulin resistance, and glucose dysmetabolism are known to increase the need for myo-inositol in particular.

Osmoregulation and Antioxidant Properties

Free-form inositols, such as myo-inositol and D-chiro-inositol, act as osmolytes to ensure adequate cellular defense against external and/or metabolic stressors. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. The exact mechanism of free radical scavenging in inositols still needs to be determined.

4. Scientific Evidence by Area of Use

4.1 Polycystic Ovary Syndrome (PCOS)

Inositol is involved in the transduction of several endocrine signals, including insulin, thyroid hormones, gonadotropins, and lipids with hormone-like activity such as prostaglandins. In the last decade, a growing body of clinical and experimental research has provided evidence about the efficiency of inositol in reversing certain clinical, metabolic, and endocrine features of PCOS.

A literature search covering PubMed until September 2020 identified 197 articles on inositols and PCOS, of which 47 were clinical trials and 35 were randomized controlled trials (RCTs). Both myo-inositol and D-chiro-inositol are involved in biochemical pathways within oocytes with roles in oocyte maturation, fertilization, implantation, and post-implantation development, and both have a role in insulin signaling and hormonal synthesis in the ovaries.

Myo-inositol, alone or in combination with its isomer D-chiro-inositol, has shown variable but significant effects in improving both symptoms and outcomes in PCOS patients. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited.

The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.

The competitive inhibition exerted by D-chiro-inositol and other small sugar-like molecules may help explain the phenomenon of "inositol resistance" — highlighted by several clinical trials — which could account for 30–40% of inositol failure in PCOS treatment. Patients should be counseled on the appropriate formulation to purchase (40:1 myo-inositol to D-chiro-inositol), as an increased D-chiro-inositol proportion may actually be of detriment.

4.2 Assisted Reproductive Technology (ART) Outcomes in PCOS

Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with PCOS necessitated a systematic review and meta-analysis. The objective was to evaluate the effect of these inositol forms on ART outcomes, with a comprehensive search conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000 to 2023.

Seventeen intervention studies were included. myo-Inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25–2.15) and top-grade embryos (RR: 1.12, 95% CI: 1.02–1.23). However, it was associated with reductions in antral follicle count and anti-Müllerian hormone levels. The meta-analysis provides evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.

4.3 Metabolic Syndrome and Cardiometabolic Outcomes

A 2025 systematic review and meta-analysis evaluated inositol's efficacy across populations both with and without diagnosed metabolic disorders, including those with conditions like obesity, non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), and PCOS. Glucose, insulin, and HOMA-IR decreased statistically significantly more following inositol consumption compared with controls. Notably, supplementation with inositol was inversely associated with BMI, waist circumference, and waist-to-hip ratio as compared with controls; however, the GRADE analyses indicated low or very low certainty, and the effects were clinically small.

In one study of 80 outpatient postmenopausal women with metabolic syndrome, women were randomly assigned to receive either myo-inositol 2 g twice daily or placebo, in addition to a low-energy diet. After 12 months of treatment, the myo-inositol group showed significant improvements in serum glucose, insulin, HOMA-IR, triglycerides, total and HDL cholesterol, and blood pressure compared to the control group, although BMI and waist circumference did not improve.

Existing studies show a high risk of bias and low certainty of evidence, particularly for anthropometric outcomes, requiring cautious interpretation. Future research should involve large-scale, rigorous trials with standardized protocols, longer follow-up, and diverse populations.

4.4 Gestational Diabetes Mellitus (GDM) and Pregnancy

A systematic review and meta-analysis including 7 RCTs with 1,321 participants found that 4 g myo-inositol supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI 0.18–0.49, p < 0.00001). It significantly decreased plasma glucose levels across fasting, 1-hour, and 2-hour oral glucose tolerance test (OGTT) measures. It also decreased the need for insulin treatment and reduced the incidence of preterm delivery and neonatal hypoglycemia.

Myo-inositol has been studied specifically in pregnant women, primarily for preventing gestational diabetes. In these trials, it did not increase the risk of preterm delivery, cesarean section, abnormally large babies, neonatal low blood sugar, or NICU admission compared to placebo. Supplementation was associated with reduced rates of gestational diabetes (11% vs. 25% in the placebo group), lower risk of preterm birth, and fewer cases of excessive birth weight.

A multicentre, double-blind, placebo-controlled pilot RCT (EMmY trial) conducted across five UK National Health Service hospitals enrolled multiethnic pregnant women at 12–15 weeks' gestation with risk factors for GDM. The intervention was 2 g of myo-inositol (plus 200 µg folic acid) or placebo, both taken twice daily until delivery. HOMA-IR and serum insulin levels were lower in the myo-inositol arm versus placebo (mean difference −0.6, 95% CI −1.2 to 0.0 for HOMA-IR).

4.5 Psychiatric Disorders: Depression, Panic Disorder, OCD

Despite its multifaceted neurobiological activities and some positive findings, data on the efficacy of inositol in the treatment of psychiatric disorders remain controversial, partly due to the heterogeneity of supporting studies. Systematic use of inositol in routine clinical practice cannot be recommended yet, although further research is encouraged.

Panic Disorder: Studies on the effectiveness of inositol in anxiety disorders began in 1995. In the first RCT conducted by Benjamin et al., inositol was more effective than a placebo in reducing the number of panic attacks experienced during the four-week trial. However, these positive results were not related to a significant improvement in the Hamilton Depression Rating Scale (HDRS) or the Hamilton Anxiety Rating Scale (HARS). The frequency and severity of panic attacks and the severity of agoraphobia declined significantly more after inositol than after placebo: a decrease from 10 attacks per week to 3 per week in the treated group, compared to a decrease from 10 to 6 in the placebo group.

Obsessive-Compulsive Disorder (OCD): Inositol was evaluated for OCD in a double-blind, controlled crossover trial. Thirteen patients with OCD completed the trial of 18 g/day of inositol or placebo for 6 weeks each. Subjects had significantly lower scores on the Yale-Brown Obsessive Compulsive Scale when taking inositol than when taking placebo. The authors concluded that inositol may be effective in a spectrum of disorders responsive to selective serotonin reuptake inhibitors.

Overall Meta-analytic Evidence: A 2014 systematic review and meta-analysis of double-blind RCTs identified seven RCTs in depression (n=242) and four RCTs in anxiety disorders (n=70). There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation. When administered as monotherapy or in addition to conventional drugs, inositol did not seem to influence clinical outcomes in both mood and psychotic disorders. Conversely, more encouraging results emerged for the treatment of panic disorders.

A review of this evidence demonstrates superiority over placebo of a second messenger precursor strategy in the treatment of depression as well as in the treatment of panic disorder and OCD. However, these are relatively small studies of a pilot nature.

4.6 Bipolar Disorder

One study by Evins et al. randomized 17 depressed bipolar adults on therapeutic levels of lithium or valproate to receive either inositol 5–20 g/day or placebo as adjunct treatment. Although the outcome was not statistically significant, notably 44% on inositol versus 0% on placebo met response criteria for symptoms of depression. Silverstone et al. showed that chronic treatment with either lithium or sodium valproate in bipolar patients may normalize PI-cycle functioning. Lithium may exert its clinical mood-stabilizing effects due to its actions on the phosphoinositol second messenger system.

4.7 Preterm Infants and Neonatal Use

Regarding respiratory distress syndrome, in preterm infants inositol appears to be helpful for treating breathing issues from underdeveloped lungs, based on preliminary research. Inositol supplementation has been linked to beneficial effects on reducing the incidence of retinopathy of prematurity (ROP); however, findings remain controversial. A meta-analysis of six studies involving 1,194 infants found that inositol supplementation showed no statistically significant effect on the incidence of severe ROP, mortality, or all stages of ROP compared with placebo, with low-to-moderate quality of evidence.

5. Body Systems and Health Areas Associated with Inositol

• Endocrine/Metabolic System: Inositol is involved in the transduction of several endocrine signals, including insulin, thyroid hormones, gonadotropins, and lipids with hormone-like activity such as prostaglandins.
• Nervous System: Inositol is commonly found in large amounts in spinal cord nerves, cerebrospinal fluid, and the brain. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity.
• Reproductive System: Both myo-inositol and D-chiro-inositol are involved in a number of biochemical pathways within oocytes, having a role in oocyte maturation, fertilization, implantation, and post-implantation development.
• Cardiovascular System: The use of inositols yields a synergistic effect for both antioxidant and insulin-sensitizing activities relevant to endothelial dysfunction.
• Liver: Biochemical functions of inositol include transmembrane signal transfer, regulation of enzyme activity, mediation of lipid transport and metabolism, and protection of the liver.
• Psychiatric/Mood Regulation: Myo-inositol imbalance is observed in psychiatric diseases and its use shows some evidence of efficacy for treatment of depression, anxiety, and compulsive disorders.

6. Dosage Forms and Dosages Reported in Studies

Experimentally, inositol dosages of up to 60 grams daily have been tried for various conditions, but doses usually fall between 1 and 4 g daily. Some uses have relatively well-established doses as reported in published studies, including 2 g for metabolic syndrome, 2 g for PCOS, 6 g for lithium-induced psoriasis, and 12 g for panic and anxiety disorders.

• PCOS and reproductive health: The typical dose in PCOS studies is 4 g per day, split into two doses of 2 g each.
• Gestational diabetes prevention: 4 g myo-inositol supplementation per day was the dose used in the systematic review meta-analysis showing significant GDM reduction. The EMmY pilot trial used 2 g of myo-inositol plus 200 µg folic acid, twice daily until delivery.
• Metabolic syndrome (postmenopausal women): Myo-inositol 2 g twice daily was studied in a 12-month trial of 80 outpatient postmenopausal women with metabolic syndrome.
• OCD: Thirteen patients with OCD completed a double-blind, controlled crossover trial of 18 g/day of inositol or placebo for 6 weeks each.
• Bipolar depression (adjunct): In one RCT, inositol was given at 5–20 g/day as adjunct treatment for bipolar depression.
• Neonatal dosing (research context): Myo-inositol has been used in preterm infants (under 29 weeks of gestational age) with respiratory distress syndrome in pharmacokinetic studies assessing daily doses of 10, 40, or 80 mg/kg/day.
• General safety threshold: Clinical trials have tested doses as high as 18 g per day for three months and 4 g per day for a full year without significant adverse effects.

7. Safety Considerations and Interactions

General Safety Profile

Myo-inositol has a strong safety profile across a wide range of doses and populations. The FDA classifies it as Generally Recognized As Safe (GRAS), permitting its use in food and even infant formula with no specific dosage limitations beyond standard manufacturing practices. Both animal model studies and several clinical trials have been conducted to evaluate the safety of inositol supplementation. Preclinical data indicate no toxic effects in terms of kidney and cognitive functions or carcinogenesis.

At the doses found in most supplements (typically 2 to 4 g per day), myo-inositol causes few if any side effects. Problems tend to show up at 12 g per day or higher, and even then they are mild: nausea, gas, diarrhea, difficulty sleeping, headache, dizziness, and tiredness.

Like many nutraceutical agents, inositol has been found to be generally well tolerated in adult RCTs. Side effects reported in available studies include mild increases in glucose, flatus, nausea, sleepiness and insomnia, dizziness, headache, and diarrhea. No drug interactions have been formally reported in adjunctive studies to date.

Bipolar Disorder

Those with bipolar disorder need to be cautious; excessive inositol might trigger manic or hypomanic episodes. Studies suggest that too much inositol may worsen bipolar disorder symptoms. This consideration is consistent with the PI-cycle hypothesis, which implicates elevated inositol signaling in manic states.

Diabetes and Hypoglycemia Risk

Because inositol increases insulin sensitivity, it may cause dangerously low blood sugar levels (hypoglycemia) in people on diabetes medications. Regular blood sugar monitoring is advised in such cases.

Mineral Absorption (High-Dose IP6)

High doses of inositol hexaphosphate (IP6) may reduce the absorption of essential minerals like zinc and iron, potentially causing nutritional deficiencies.

Pregnancy

Myo-inositol has been studied specifically in pregnant women, primarily for preventing gestational diabetes. In these trials, it did not increase the risk of preterm delivery, cesarean section, abnormally large babies, neonatal low blood sugar, or NICU admission compared to placebo. No significant adverse effects were reported in association with inositol supplementation in the RCTs included in a 2025 meta-analysis.

Duration of Safety Data

Inositol has been shown to be safe for short-term use, typically up to ten weeks, based on existing data. The myo-inositol and D-chiro-inositol combination (40:1 ratio) has been used in clinical trials for six months with no relevant side effects recorded.

References

• PubChem CID 892 – Inositol (NIH/NLM)
• USDA Agricultural Marketing Service – Inositol Technical Report
• Bizzarri M et al. – The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. PMC (2020)
• Arroyo-Escribano J et al. – Role of Inositols and Inositol Phosphates in Energy Metabolism. PMC (2020)
• Bevilacqua A, Bizzarri M – Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies. PMC (2021)
• Ferretti G et al. – Novel Chemical and Biological Insights of Inositol Derivatives in Mediterranean Plants. PubMed (2022)
• Bizzarri M et al. – PCOS and Inositols: Controversial Results and Necessary Clarifications. PMC (2021)
• Kamenov Z, Gateva A – Inositols in PCOS. Molecules (2020)
• Systematic review and meta-analysis: myo-inositol on ART outcomes in PCOS. PMC (2025)
• Costello MF et al. – Inositol for PCOS: Systematic Review and Meta-analysis for the 2023 International Evidence-based PCOS Guidelines. JCEM (2024)
• Unfer V et al. – Effects of Inositol(s) in Women with PCOS: A Systematic Review of RCTs. PMC (2016)
• Pkhaladze L et al. – Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. PMC (2017)
• Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: GRADE-assessed systematic review and meta-analysis. Diabetology & Metabolic Syndrome / PMC (2025)
• Azzini E et al. – Neurobiology and Applications of Inositol in Psychiatry: A Narrative Review. PMC (2023)
• Fux M et al. – Inositol treatment of obsessive-compulsive disorder. PubMed (1996)
• Belmaker RH et al. – Controlled trials of inositol in psychiatry. European Neuropsychopharmacology (1997)
• Mukai T et al. – A meta-analysis of inositol for depression and anxiety disorders. Human Psychopharmacology (2014)
• NCBI Bookshelf – DARE Quality-assessed Review: Meta-analysis of inositol for depression and anxiety disorders
• Matarrelli B et al. – Inositol Nutritional Supplementation for the Prevention of GDM: Systematic Review and Meta-analysis. PMC (2022)
• Johns EC et al. – Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY trial). PMC (2022)
• Croze ML, Soulage CO – Myo-inositol for insulin resistance, metabolic syndrome, PCOS and gestational diabetes. PMC (2022)
• Fraticelli F et al. – Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. PMC (2019)
• Du Y et al. – The efficacy and safety of inositol supplementation in preterm infants to prevent retinopathy of prematurity: a systematic review and meta-analysis. PMC (2019)
• Matarrelli B et al. – Myoinositol in the Prevention of Gestational Diabetes Mellitus. Journal of Diabetes Research (2019)
• Frontiers in Endocrinology – Unexpected effects of treating insulin-resistant obese women with high-dose D-chiro-inositol (2025)
• EBSCO Research Starters – Inositol as a Dietary Supplement
• ScienceDirect Topics – Inositol Overview
• Frontiers in Nutrition – Myo-inositol supplementation in gestational diabetes mellitus: is there any interference with diet? (2025)